Last edition
News about "Prolaris Prostate Cancer Prognostic Test "
Zydus Lifesciences Inks Exclusive Deal with Myriad Genetics for Cancer Risk Tests in India
Zydus Lifesciences has entered into an exclusive agreement with US-based Myriad Genetics to introduce clinically validated cancer-risk assessment diagnostic tests in India, aimed at enabling personalised, evidence-based cancer care and strengthening early detection and preventive oncology efforts in the country.
Prolaris Prostate Cancer Prognostic Test | 19/12/2025 | By News Bureau | 159
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy